Roche Diagnostics Doubles Down on China with $1.15 Billion Investment and New Suzhou Facility
Recently, Roche Diagnostics (Suzhou) Limited officially signed an agreement with the Administrative Committee of Suzhou Industrial Park for a new investment project at its Suzhou facility. The primary objective of this investment is to provide space for further capacity expansion. The initial installment amounts to RMB 3 billion, with the total investment reaching CHF 1 billion (approximately RMB 8.3869 billion).
Marco Cairoli, General Manager of Roche Diagnostics’ Asia-Pacific Production Base and R&D Center, stated, “Roche Diagnostics has established robust end-to-end capabilities at its Suzhou site, encompassing R&D, manufacturing, and logistics. As a key manufacturing and R&D hub, the new investment in Suzhou will facilitate the introduction of high-quality products into the Chinese market and ensure sustainable supply across the Asia-Pacific region.”
Clearly, this investment is neither Roche Diagnostics’ first in China nor its last.
This year marks the 30th anniversary of Roche Group’s entry into the Chinese market. Since the groundbreaking of Shanghai Roche Pharmaceuticals in Zhangjiang, Shanghai, in 1994, Roche Group has continuously upgraded and perfected its complete value chain in China, encompassing R&D, development, manufacturing, and marketing.
In the pharmaceutical sector, Roche (Pharma) currently has more than 20 products on the Chinese market, covering eight major therapeutic areas. Meanwhile, Roche (Pharma) is also intensifying its investments in building out its industrial chain.
From the additional investment of RMB 863 million in 2019 to upgrade the R&D center into the Roche Shanghai Innovation Center, to the RMB 300 million invested in 2021 to establish the Roche China Accelerator and empower the development of China’s local healthcare industry, and further to the addition of only RMB 250 million in working capital in 2022... Roche (Pharmaceuticals) invested more than RMB 1.4 billion in China during the three-year period from 2019 to 2022 alone.
Alongside its additional investments, Roche (Pharmaceuticals) is also continuously seeking integrated development with local innovation. For instance, Huashen Zhiyao, an AI-driven biopharmaceutical company, has engaged in R&D collaboration with the Roche China Innovation Center on an AI-powered platform for modeling and designing large-molecule biologics. As of the end of June 2023, more than ten Chinese start-ups had become members of the Roche Accelerator, gaining access to resources such as funding channels, partnership opportunities, and R&D expertise.
Roche Diagnostics has adopted a similar strategy in the Chinese market. Although it entered China slightly later than Roche Pharmaceuticals, Roche Diagnostics has been present in the country for over 20 years. Over these two decades, Roche Diagnostics has launched more than 100 products. An analysis of its new releases in 2023 reveals that automation, intelligence, precision medicine, early screening and diagnosis, and improving the accessibility of advanced testing technologies have become the key trends in its product development.
Notably, in April this year, Roche Diagnostics’ innovative immunoassay product, Elecsys CA 242, was officially approved in China. As the first locally developed innovative product designed by Roche Diagnostics specifically to meet the healthcare needs of the Chinese market, it aims to support treatment monitoring and comprehensive disease management for gastrointestinal malignancies, such as pancreatic cancer and colorectal cancer.
In terms of supply chain development, Roche Diagnostics invested in the establishment of its Asia-Pacific production base in Suzhou in 2015; in 2018 and 2020, it launched its Asia-Pacific R&D Center and invested in the construction of a system reagent manufacturing base, respectively; in 2021 and 2023, Roche Diagnostics successively introduced PCR sample preservation kits and pathology laboratory platform reagent projects, and established its Asia-Pacific instrument production base.
In September 2023, Roche Diagnostics’ China Technology Innovation Center officially commenced operations. The center integrates and upgrades Roche Diagnostics’ original training facility, dedicated to empowering the development of high-quality technical talent and incubating innovative technological solutions. This initiative aims to achieve a leap in the quality and efficiency of medical services, thereby fostering a new smart ecosystem for laboratory diagnostics.
For Roche Diagnostics, this collaboration with the Suzhou Industrial Park essentially represents an upgrade of its supply chain capabilities in the Chinese market.
Specifically, the project covers a construction area of approximately 120,000 square meters and is scheduled to commence official production in 2028. Upon completion, Roche Diagnostics’ Asia-Pacific production base and R&D center plan to launch approximately 400 reagent and instrument products, including a substantial number of high-quality reagents specifically tailored for Chinese patients.
Indeed, it is hardly surprising that multinational giants are expanding their presence in the Chinese market.
For example, GE Healthcare has invested in the construction of five major bases in China, encompassing six large factories. Data disclosed by GE Healthcare in 2023 shows that over 78% of the products it sells in China are domestically produced, and equipment manufactured in China is also exported to overseas markets. This appears to indirectly confirm that the integrated development of GE Healthcare with local innovation in China is progressing well.
Take Siemens Healthineers as another example. After announcing its new China market strategy in 2022, the company injected an additional investment of over RMB 1 billion in 2023 to establish a new R&D and manufacturing base for high-end medical equipment in Shenzhen. According to Siemens Healthineers’ financial report, approximately 75% of the products sold by the company in China during the second quarter of 2023 were locally manufactured.
In addition to these “long-standing partners,” the Chinese market has continued to welcome new entrants in recent years. In 2023, Olympus, a global leader in endoscopy, announced the establishment of a production and R&D base for medical devices in China. This marks the first time that Olympus has manufactured its core products outside Japan. Upon completion, the facility will strengthen manufacturing capabilities and establish and expand R&D functions tailored to the characteristics of the Chinese market, becoming a global strategic hub for Olympus that integrates manufacturing, R&D, procurement, and solutions.
However, it must be noted that multinational corporations are facing challenges in the Chinese market in recent years. On one hand, changes in the policy environment in China, including the implementation of centralized procurement, Diagnosis-Related Groups (DRG), and policies related to compliance in pharmaceutical marketing, have inevitably had a certain impact on corporate revenues.
On the other hand, domestic Chinese companies are also catching up rapidly. An increasingly pronounced trend of import substitution is emerging across more and more sectors, with China even taking the lead in development in some areas. This is inevitably exerting certain pressures on multinational giants.
For instance, in the high-end IVD total laboratory automation (TLA) sector, Mindray Medical has risen to the top based on the number of publicly announced contracts in the Chinese market during the first half of 2024, surpassing IVD giants such as Roche Diagnostics, Abbott, and Siemens Healthineers. Furthermore, at a recent investor relations meeting, Mindray Medical revealed that its domestic market share for chemiluminescence immunoassay business is expected to overtake another imported brand this year.
Consequently, in the face of an evolving policy landscape and increasingly formidable Chinese “competitors,” some foreign enterprises have chosen to exit the Chinese market or scale back their operations there. However, a greater number of companies have opted to stay or even increase their investments. For these firms, the primary challenges now lie in strategically adapting with agility to policy shifts and striking a balance between cooperation and competition when partnering with local Chinese enterprises.